Hypertension Guidelines



Similar documents
Cardiovascular Risk in Diabetes

Diabetic nephropathy is detected clinically by the presence of persistent microalbuminuria or proteinuria.

Hypertension and Heart Failure Medications. Dr William Dooley

Hypertension Guideline V4

Management of High Blood Pressure in Adults Based on the Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC8)

Drug Treatment in Type 2 Diabetes with Hypertension

SPECIALTY : CARDIOLOGY CLINICAL PROBLEM: HEART FAILURE

HYPERTENSION ASSOCIATED WITH RENAL DISEASES

Chronic Kidney Disease (CKD) Algorithm. Chronic Kidney Disease (CKD) Algorithm Page 1

Guideline for Microalbuminuria Screening

Initiate Atorvastatin 20mg daily

Case Study 6: Management of Hypertension

Absolute cardiovascular disease risk

ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes

Diabetes and the Kidneys

Drug treatment of elevated blood pressure

ADULT HYPERTENSION PROTOCOL STANFORD COORDINATED CARE

Absolute cardiovascular disease risk management

In many diabetes units, people with type

CHAPTER 8 ANTIHYPERTENSIVE DRUGS

Renal Disease in Type 2 Diabetes Mellitus

PRESCRIBING GUIDELINES FOR LIPID LOWERING TREATMENTS for SECONDARY PREVENTION

Hypertension. Clinical management of primary hypertension in adults. This guideline partially updates and replaces NICE clinical guideline 34

Guidelines for the management of hypertension in patients with diabetes mellitus

Trends in Prescribing of Drugs for Type 2 Diabetes in General Practice in England (Chart 1) Other intermediate and long-acting insulins

EXPLORING THE INTERACTION BETWEEN EXERCISE AND MEDICATION FOR CHRONIC DISEASE: CONSIDERATIONS FOR FITNESS PROFESSIONALS

Case study 28: Managing hypertension in diabetes

Secondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence

Antihypertensive Drug Management to Achieve Systolic Blood Pressure <120 mmhg in SPRINT

Diabetic Nephropathy

SUMMARY OF CHANGES TO QOF 2015/16 - ENGLAND CLINICAL

DISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD

Understanding diabetes Do the recent trials help?

DRUG UTILIZATION EVALUATION OF ANTIHYPERTENSIVE DRUGS IN DIABETIC PATIENTS WITH CKD

Guidance for Industry Hypertension Indication: Drug Labeling for Cardiovascular Outcome Claims

Dorset Cardiac Centre

Chronic Kidney Disease and the Electronic Health Record. Duaine Murphree, MD Sarah M. Thelen, MD

Type 2 diabetes and hypertension in older adults:a case study

Rivaroxaban: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF

High Blood Cholesterol

CLINICAL GUIDELINE FOR SECONDARY PREVENTION AFTER STROKE OR TIA (PRIMARY AND SECONDARY CARE CORNWALL) MANAGEMENT 1. Aim/Purpose of this Guideline

Summary of QOF indicators

Statin Template Guidance Use of statins in primary and secondary prevention of vascular disease Endorsed by ABHB MTC for use in Gwent (October 2012)

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. sacubitril/valsartan film-coated tablets

Cardiovascular disease physiology. Linda Lowe-Krentz Bioscience in the 21 st Century October 14, 2011

Special Communication

The Canadian Diabetes Association s 2013 Clinical Practice Guidelines and the Pharmacist Rob Roscoe, B.Sc.Pharm., ACPR, CDE, CPT

Tackling the Semantic Interoperability challenge

Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results

Treatment of Hypertension: JNC 8 and More

Case Study 8: Heart Failure

CONGESTIVE HEART FAILURE PATIENT TEACHING

Board Review: Hypertension Cases

DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF)

How To Treat Dyslipidemia

HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below

Getting the most from blood pressure medicines

Prescribing Framework for Donepezil in the Treatment and Management of Dementia

High Blood Pressure (Essential Hypertension)

Chronic Kidney Disease

Shared Care Guideline-Use of Donepezil, Galantamine, Rivastigmine and Memantine in Dementia

Upstate University Health System Medication Exam - Version A

Hypertension and Diabetes

ACUTE STROKE UNIT ORIENTATION

TA 256: Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation

JNC-8 Blood Pressure and ACC/AHA Cholesterol Guideline Updates. January 30, 2014

Southern Derbyshire Shared Care Pathology Guidelines. AKI guidelines for primary care

SHORT CLINICAL GUIDELINE SCOPE

A Patients Guide to Heart Failure

Heart Failure: Diagnosis and Treatment

ACCIDENT AND EMERGENCY DEPARTMENT/CARDIOLOGY

Medical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South

Microalbuminuria: We are in the midst of an epidemic: the epidemic. So What s a Little Protein? Malcolm s diabetes. How much is too much?

Rivaroxaban: Prescribing Guidance for the treatment of provoked venous thromboembolism (VTE)

Prevalence and risk factor of chronic kidney disease in elderly diabetic patients in Korea 성애병원 내과 김정한

Optimal Treatment of Drug Resistant Hypertension PATHWAY-2

Can Common Blood Pressure Medications Cause Diabetes?

Easy or complex? University Pharmacy. Pharm.D. candidates, 2011

High Blood Pressure and Chronic Kidney Disease

Most probable Diagnosis

DOI: /jch Official Journal of the American Society of Hypertension, Inc. The Journal of Clinical Hypertension 1

Shared Care Protocol for the Prescription of Memantine for Alzheimer s disease

Hypertension Best Practices Symposium

2013 ACO Quality Measures

InDependent Diabetes Trust

COMPARING TWO KINDS OF BLOOD PRESSURE PILLS:

High Blood pressure and chronic kidney disease

Transcription:

Overview Hypertension Guidelines Aim to reduce Blood Pressure to 140/90 or less (140/80 for diabetics), adding drugs as needed until further treatment is inappropriate or declined. N.B. patients do not need to be swapped immediately onto this pathway if stable on previous pathways Younger than 55 years 55 years or older or African/Caribbean descent of any age Ramipril 2.5-10mg OD (Candesartan 8-32mg OD or Losartan 50-100mg if ACE not tolerated) Amlodipine 5-10mg OD (or alternative as above) Indapamide 2.5mg OD Amlodipine 5-10mg OD (Lacidipine 2-6mg or Lercanidipine 10-20 mg if ankle swelling) Ramipril 2.5-10mg OD (or alternative as above) Fourth Line Agent (Resistant Hypertension) i. Spironolactone 25mg OD (if potassium <4.5mmol/l) (unlicensed) ii. Bisoprolol 1.25 to 10mg OD iii. Doxazosin 1-16mg daily Consider an ACE Inhibitor first-line for patients with Diabetes or Impaired Glucose Intolerance. NB; Lisinopril could be used instead of Ramipril if practices prefer Review Date: January 2014 1

Review Date: January 2014 2

General Principles 1. Clinic BP >140/90 leads to Ambulatory Blood Pressure Monitoring (ABPM) 2. ABPM uses average of at least 14 readings taken during waking hours 3. Offer antihypertensive drug to all under 80 with Stage 1 hypertension with: o Target organ damage (high albumin:creatinine ratio, haematuria, raised creatinine, low egfr, hypertensive retinopathy, LVH) o Established cardiovascular disease o Renal disease o Diabetes o 10 year Cardiovascular risk >20% 4. Offer antihypertensive drug to all with stage 2 hypertension 5. Same medications for over 80s 6. Consider specialist evaluation in people with hypertension under 40 as 10 year cardio-vascular risk score underestimates risk 7. All patients should be given lifestyle advice at every opportunity. The following are average reductions in blood pressure seen in trials: Diet (healthy low calorie) Exercise (aerobic 30-60min 3-5x/wk) Relaxation therapy (structured) Alcohol reduction (structured) Salt reduction (<6g.day) 5-6mmHG 2-3mmHg 3-4mmHg 3-4mmHg 2-3mmHg 8. Treatment should be started with lowest recommended dose and titrated up (except indapamide and spironolactone) until control achieved, treatment not tolerated or maximum dose reached. 9. next drug in, if target not reached do not stop existing treatment unless side effects cannot be tolerated or there has been no response after 4 weeks (3 months thiazide-like diuretics) 10. Allow at least 4 weeks to observe the full response 11. 60% of patients will require more than 1 drug to control blood pressure 12. Check compliance to treatment if little or no benefit seen BP Target = less than 140/90mmHg (NICE) BP Target = less than 140/80mmHg if diabetic (NICE) BP Target = less than 135/75mmHg if diabetic + microalbuminuria or proteinuria present (NICE) QoF BP Target = 150/90mmHg QoF BP Target in diabetes 145/85mmHg Hypertension continuing treatment A bi-annual review of BP should occur. Patients motivated to make lifestyle changes and who want to stop using antihypertensives, if CVD risk is low and BP well controlled should be offered a trial reduction or withdrawal of therapy and a regular review. Annual U+Es, cholesterol, LFTs (if on statin), glucose Review Date: January 2014 3

Hypertension Treatment Information ACE inhibitor= Ramipril 2.5mg Once Daily (1.25mg in elderly/frail) Titrate up to a maximum of 10mg once daily or until BP controlled U+E needed before treatment. BP and U+E needed 2 weeks after starting or increasing dose If the patient is unable to tolerate an ACE inhibitor due to coughing; (clinical trials demonstrate that 1 patient in every 15-20 is unable to tolerate an ACE due to cough) Candesartan can be used as an alternative 8mg Once daily initially (lower doses in renal/hepatic failure ). U+E needed before treatment. BP and U+E needed 2 weeks after starting or increasing dose. Titrate up to max tolerated dose if control not achieved (max 32mg once daily. Losartan 50mg with increase to 100mg is an alternative) Common Contraindications: Aortic stenosis, Renovascular disease, Serum creatinine above 150mmol/l caution GP, Lithium therapy, Known hypersensitivity Watch potassium if amiloride/spironolactone co-prescribed First dose hypotension especially if frail/elderly give at night Postural hypotension dizziness on standing Caution required if patient is receiving high-dose diuretic therapy more than 80mg fruosemide daily or its equivalent. Caution required in peripheral vascular disease or generalised atherosclerosis owing to risk of clinically silent renovascular disease. Calcium Channel Blocker = Amlodipine maleate 5mg Once daily Start 5mg once daily Max daily dose 10mg once daily Common Contraindications:Unstable angina, Aortic Stenosis May cause ankle oedema which will not respond fully to diuretics. Different classes of calcium channel blocker have different indications/contraindications. If not prescribing amlodipine, check BNF Review Date: January 2014 4

Thiazide-like diuretic = Indapamide 2.5mg Once daily No titration If a patient is already on a beta-blocker for another condition move to the next step to avoid the increasing the risk of developing diabetes with the thiazide-like/beta-blocker combination Common Contraindications:Severe renal/hepatic disease, Hypokalaemia, Hyponatraemia, Hypercalaemia, Recent history of Gout, Lithium therapy Immobile patients may find it problematic visiting the toilet more frequently Caution if loop diuretic is co-prescribed (Furosemide, Bumetanide) Fourth Line Agents Spironolactone 25mg od if potassium <4.5 mmol/l Common Contraindications: hyperkalaemia, hyponatraemia, ison s Disease unlicensed preparation so patient needs to be informed caution with low egfr due to higher risk of hyperkalaemia Bisoprolol 1.25-10mg od Common Contraindications: asthma, heart block, uncontrolled heart failure, severe peripheral artery disease Avoid in combination with Thiazide- like diuretic in people at higher risk of Diabetes (obese, family history etc) Doxazosin 1-16mg daily Poor evidence for reduction in events Review Date: January 2014 5